Efficacy and safety of Pemafibrate administration in patients with dyslipidemia: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials.-Reference-Cited by-同舟云学术

Efficacy and safety of Pemafibrate administration in patients with dyslipidemia: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials.

Published:2024-07-16 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Elbahloul Mohammed A.¹,Elgadi Ammar²,Fayed Hossam³,Ramadan Mohamed⁴,Kasser Mohamed E.¹,Hussein Ahmed⁵,Labieb Fatma⁶

Affiliation:

1. Kafr El-Shaikh University

2. University of Khartoum

3. Al-Azhar University

4. Suez University

5. New Damietta University

6. Beni-Suef University

Abstract

Background:Patients with dyslipidemia are at risk for cardiovascular diseases. Lowering levels of lipid decreases morbidity. Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator (SPPARMα) that works better at lowering serum triglycerides. Methods: Clinical trials investigating the effect of pemafibrate on lipid biomarkers in patients with dyslipidemia were searched in PubMed, Ovid Medline, SCOPUS, Web of Science (WOS), and the Cochrane Library from inception till December 31, 2023. The data were pooled as mean difference, odds ratio (OR), and 95% confidence interval (CI). Results: 14 clinical trials were eligible involving 12451 patients showed favorable triglyceride level change (MD: -49.60 [-62.64, -36.55] P<0.00001) for pemafibrate compared to placebo. Pemafibrate showed a significant increase in HDL-C levels (MD: 14.57 [10.14, 19.01] P<0.00001) but showed a concurrent increase in LDL-C levels (MD: 10.99 [6.10, 15.88] P <0.00001). It also showed non-HDL-C, total cholesterol level, Apo B, Apo C-II, and Apo C-III to be significantly reduced in pemafibrate groups. Also, in pemafibrate groups, hepatic adverse events were reported less frequently than in placebo groups. No significant difference was found in the frequency of total adverse effects, adverse drug reactions, or serious adverse events between the pemafibrate and placebo groups. Conclusion:Pemafibrate improved the overall lipid biomarkers compared to placebo groups, demonstrating a significant reduction in triglycerides, non-HDL-C, and total cholesterol while increasing in HDL-C. Moreover, there was no significant difference in adverse effects.

Publisher

Springer Science and Business Media LLC

Reference39 articles.

1. Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M et al. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis [Internet]. 2023;383:117312. https://linkinghub.elsevier.com/retrieve/pii/S0021915023052334.

2. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol [Internet]. 2021;18(10):689–700. https://www.nature.com/articles/s41569-021-00541-4.

3. Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol [Internet]. 2017;14(7):401–11. https://www.nature.com/articles/nrcardio.2017.31.

4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll Cardiol [Internet]. 2020;76(25):2982–3021. https://linkinghub.elsevier.com/retrieve/pii/S0735109720377755.

5. Du Z, Qin Y, Dyslipidemia, Disease C. Current Knowledge, Existing Challenges, and New Opportunities for Management Strategies. J Clin Med [Internet]. 2023;12(1):363. https://www.mdpi.com/2077-0383/12/1/363.